Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02717455 · OUTCOME

Progression-free Survival (PFS) in Stratum 2

Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma · Source last updated 2024-04-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
Full Range
Time frame
From date on treatment until date of PD or death due to any cause or date of last follow-up

What was measured

PFS was measured from the time of treatment initiation until the time of progressive disease (PD) or death due to any cause for patients with an event, or until the time of last follow-up for patients who were progression free.

Analysis population: Non-progressed DIPG or H3K27M+ thalamic DMG patients who were enrolled on stratum 2 and received at least one dose of panobinostat were included in the analysis. Per the associated protocol objective, all dose levels on stratum 2 were combined to estimate the PFS for this stratum. Two patients who did not start protocol therapy were excluded.

Groups in this outcome

Stratum 2

Non-progressed DIPG or H3K27M+ thalamic DMG patients who were treated with the "3 times/week, every other week" schedule.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Stratum 232

Reported measurements

Source class 1
Values in months · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Stratum 23.83Not reported0.2314.93Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.23
        upper Limit
        14.93
        value
        3.83
denoms
  1. counts
    1. group Id
      OG000
      value
      32
    units
    Participants
description
PFS was measured from the time of treatment initiation until the time of progressive disease (PD) or death due to any cause for patients with an event, or until the time of last follow-up for patients who were progression free.
dispersion Type
Full Range
groups
  1. description
    Non-progressed DIPG or H3K27M+ thalamic DMG patients who were treated with the "3 times/week, every other week" schedule.
    id
    OG000
    title
    Stratum 2
param Type
MEDIAN
population Description
Non-progressed DIPG or H3K27M+ thalamic DMG patients who were enrolled on stratum 2 and received at least one dose of panobinostat were included in the analysis. Per the associated protocol objective, all dose levels on stratum 2 were combined to estimate the PFS for this stratum. Two patients who did not start protocol therapy were excluded.
reporting Status
POSTED
time Frame
From date on treatment until date of PD or death due to any cause or date of last follow-up
title
Progression-free Survival (PFS) in Stratum 2
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice